Lundbeck

Illinois Biotechnology Industry Organization adds to board of directors

Thursday, December 11, 2014 10:51 AM

The Illinois Biotechnology Industry Organization (iBIO) has elected several new additions to its board of directors. The new board members include Daniel Brennan of Lundbeck U.S., Jamie Oldani of Eli Lilly, Susanne Resatz of Vetter Development Services USA and Geeta Vemuri of Baxter Ventures.

More... »


Otsuka to acquire Avanir for $3.5 billion

Tuesday, December 2, 2014 11:32 AM

Tokyo-based Otsuka Pharmaceutical will acquire Avanir Pharmaceuticals of Aliso Viejo, Calif., for $17 per share in cash, for a total value of approximately $3.5 billion.

More... »


Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

Lundbeck completes acquisition of Chelsea Therapeutics

Wednesday, June 25, 2014 02:06 PM

Lundbeck has completed its acquisition of Chelsea Therapeutics International for $6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional $1.50 per share upon achievement of certain sales milestones.

More... »

Lundbeck to acquire Chelsea Therapeutics

Friday, May 9, 2014 12:25 PM

H. Lundbeck of Denmark and North Carolina-based Chelsea Therapeutics International have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

More... »

Lieber Institute forms consortium to develop brain disorder treatments

Wednesday, April 9, 2014 12:31 PM

The Lieber Institute for Brain Development (LIBD), an independent nonprofit, and pharmaceutical companies Astellas, Eli Lilly, Lundbeck, Pfizer and Roche are participating in an early-stage research consortium to analyze RNA, the genomic and epigenetic data obtained from human brains. The goal of the consortium is to expand knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

Otsuka, Lundbeck partner in Japan

Friday, November 1, 2013 11:16 AM

H. Lundbeck and Otsuka Pharmaceutical said their existing alliance now also includes development and commercialization of nalmefene (sold under the brand name Selincro in Europe) in Japan. Earlier this year, nalmefene was approved by the EMA as the first treatment for the reduction of alcohol consumption.

More... »

MJFF donates $1 million for two Lundbeck research projects

Wednesday, October 16, 2013 10:26 AM

Danish pharmaceutical company Lundbeck has been awarded two research grants totaling $1 million from The Michael J. Fox Foundation (MJFF) for Parkinson's research.  

More... »

Lundbeck simplifies and restructures, 200 jobs to be cut

Monday, September 30, 2013 03:40 PM

Lundbeck, a global pharmaceutical company specialized in brain diseases, has simplified its commercial structure, increased alignment across countries and improved competencies and investments in market access as a result of its Fit-for-the-Future program.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs